Wedbush Lowers Audentes Therapeutics (NASDAQ:BOLD) to Neutral

Audentes Therapeutics (NASDAQ:BOLD) was downgraded by investment analysts at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Tuesday, The Fly reports.

BOLD has been the topic of a number of other reports. Mizuho reissued a “buy” rating and set a $45.00 price target on shares of Audentes Therapeutics in a research note on Wednesday, August 7th. BMO Capital Markets lowered shares of Audentes Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday. Citigroup upgraded shares of Audentes Therapeutics from a “sell” rating to a “neutral” rating in a report on Tuesday. Robert W. Baird upgraded shares of Audentes Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Tuesday. Finally, ValuEngine lowered shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $42.00.

NASDAQ BOLD opened at $28.61 on Tuesday. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -8.41 and a beta of 1.77. Audentes Therapeutics has a twelve month low of $17.95 and a twelve month high of $41.65. The business’s fifty day moving average is $27.71 and its 200 day moving average is $33.11.

Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.07. During the same period last year, the firm posted ($0.97) earnings per share. Equities research analysts anticipate that Audentes Therapeutics will post -4.13 EPS for the current year.

In other Audentes Therapeutics news, Director Louis G. Lange sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $32.16, for a total transaction of $321,600.00. Following the completion of the transaction, the director now owns 276,044 shares in the company, valued at approximately $8,877,575.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Matthew R. Patterson sold 14,426 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $30.00, for a total transaction of $432,780.00. Following the transaction, the chief executive officer now owns 127,820 shares of the company’s stock, valued at approximately $3,834,600. The disclosure for this sale can be found here. Corporate insiders own 5.30% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Great Point Partners LLC raised its stake in Audentes Therapeutics by 29.2% during the third quarter. Great Point Partners LLC now owns 2,485,000 shares of the biotechnology company’s stock worth $69,804,000 after buying an additional 562,063 shares during the last quarter. BlackRock Inc. lifted its holdings in Audentes Therapeutics by 14.2% in the second quarter. BlackRock Inc. now owns 3,333,445 shares of the biotechnology company’s stock valued at $126,204,000 after buying an additional 413,768 shares during the period. D. E. Shaw & Co. Inc. lifted its holdings in Audentes Therapeutics by 118.6% in the second quarter. D. E. Shaw & Co. Inc. now owns 592,947 shares of the biotechnology company’s stock valued at $22,449,000 after buying an additional 321,756 shares during the period. Millennium Management LLC lifted its holdings in Audentes Therapeutics by 49.2% in the third quarter. Millennium Management LLC now owns 773,279 shares of the biotechnology company’s stock valued at $21,721,000 after buying an additional 255,086 shares during the period. Finally, Nuveen Asset Management LLC bought a new stake in Audentes Therapeutics during the second quarter valued at $8,653,000. Institutional investors own 98.08% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

See Also: Economic Reports

The Fly

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.